Equities research analysts forecast that Agios Pharmaceuticals (NASDAQ:AGIO) will announce earnings per share (EPS) of ($1.66) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Agios Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.69) and the highest estimate coming in at ($1.62). Agios Pharmaceuticals posted earnings of ($1.78) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 6.7%. The firm is expected to issue its next earnings results on Tuesday, August 14th.
On average, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.51) per share for the current year, with EPS estimates ranging from ($6.73) to ($6.40). For the next financial year, analysts anticipate that the company will post earnings of ($4.83) per share, with EPS estimates ranging from ($6.30) to ($0.89). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Agios Pharmaceuticals.
Get Agios Pharmaceuticals alerts:Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.03). The company had revenue of $8.80 million for the quarter, compared to analysts’ expectations of $11.93 million. Agios Pharmaceuticals had a negative net margin of 822.32% and a negative return on equity of 61.70%. The business’s revenue for the quarter was down 16.2% compared to the same quarter last year. During the same period last year, the company posted ($1.56) EPS.
A number of analysts have recently weighed in on the company. Credit Suisse Group set a $95.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 7th. SunTrust Banks set a $115.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 7th. ValuEngine raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Cann reissued a “hold” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 17th. Finally, BidaskClub raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 3rd. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $88.40.
NASDAQ:AGIO opened at $86.99 on Wednesday. The company has a market cap of $4.95 billion, a PE ratio of -12.89 and a beta of 1.98. Agios Pharmaceuticals has a fifty-two week low of $45.96 and a fifty-two week high of $89.33.
In related news, insider Steven L. Hoerter sold 2,050 shares of the firm’s stock in a transaction on Monday, April 23rd. The stock was sold at an average price of $85.95, for a total value of $176,197.50. Following the completion of the sale, the insider now owns 2,050 shares of the company’s stock, valued at $176,197.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Bowden sold 2,000 shares of the firm’s stock in a transaction on Thursday, April 12th. The stock was sold at an average price of $85.10, for a total value of $170,200.00. Following the completion of the sale, the insider now directly owns 2,881 shares of the company’s stock, valued at approximately $245,173.10. The disclosure for this sale can be found here. Insiders sold 62,950 shares of company stock valued at $5,102,838 in the last ninety days. 3.02% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Profund Advisors LLC raised its holdings in Agios Pharmaceuticals by 4.3% in the first quarter. Profund Advisors LLC now owns 15,875 shares of the biopharmaceutical company’s stock worth $1,298,000 after purchasing an additional 649 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Agios Pharmaceuticals by 41.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 762 shares in the last quarter. California Public Employees Retirement System raised its holdings in Agios Pharmaceuticals by 3.4% in the third quarter. California Public Employees Retirement System now owns 36,100 shares of the biopharmaceutical company’s stock worth $2,410,000 after purchasing an additional 1,200 shares in the last quarter. State of Wisconsin Investment Board raised its holdings in Agios Pharmaceuticals by 15.7% in the first quarter. State of Wisconsin Investment Board now owns 9,904 shares of the biopharmaceutical company’s stock worth $810,000 after purchasing an additional 1,345 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in Agios Pharmaceuticals by 74.8% in the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 1,520 shares in the last quarter. Institutional investors and hedge funds own 82.13% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment